PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection.

McQuade, Rachel M; Stojanovska, Vanesa; Bornstein, Joel C; Nurgali, Kulmira

McQuade, Rachel M; Stojanovska, Vanesa; Bornstein, Joel C; Nurgali, Kulmira.

Afiliación

McQuade RM; College of Health and Biomedicine, Institute for Health and Sport, Victoria University, Melbourne, Australia.
Stojanovska V; College of Health and Biomedicine, Institute for Health and Sport, Victoria University, Melbourne, Australia.
Bornstein JC; Department of Physiology, Melbourne University, Melbourne, Australia.
Nurgali K; College of Health and Biomedicine, Institute for Health and Sport, Victoria University, Melbourne, Australia; Department of Medicine Western Health, Melbourne University, Melbourne, Australia; Australian Institute of Musculoskeletal Science (AIMSS), Melbourne, Australia. Electronic address: kulmira.

Pharmacol Res ; 137: 104-113, 2018 11.

Article en En | MEDLINE | ID: mdl-30278221

Asunto(s)

Antineoplásicos/efectos adversos; Neuroprotección/efectos de los fármacos; Inhibidores de Poli(ADP-Ribosa) Polimerasas/uso terapéutico; Animales; Carboplatino/efectos adversos; Cisplatino/efectos adversos; Sinergismo Farmacológico; Humanos; Enfermedades Intestinales/inducido químicamente; Enfermedades Intestinales/tratamiento farmacológico; Síndromes de Neurotoxicidad/tratamiento farmacológico; Oxaliplatino/efectos adversos; Enfermedades del Sistema Nervioso Periférico/inducido químicamente

Palabras clave

Mitochondrial dysfunction; Neuropathy; Neuroprotection; Oxidative stress; PARP; Platinum chemotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inhibidores de Poli(ADP-Ribosa) Polimerasas / Neuroprotección / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: Pharmacol Res Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Australia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google